147841 20250109150035.0 doi 10.1038/leu.2014.184 sideral 129720 ART-2014-129720 eng Fernández-Rodríguez, C MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma 2014 Diffuse large B-cell lymphoma (DLBCL) encompasses an aggressive and heterogeneous group of malignancies. Gene expression profiling (GEP) unraveled two main subtypes based on their putative cell of origin named germinal center B-cell-like (GCB) and activated B-cell-like (ABC), with specific genetic alterations and different clinical outcome. Recent studies have reported several somatic mutations in the myeloid differentiation primary response gene 88 (MYD88) affecting B-cell lymphomas. Among them, the leucine to proline exchange at position 265 (L265P) is the most recurrent and biologically potent MYD88 variation, being found in about 30% of ABC-DLBCL but uncommon in GCB-DLBCL. Here, we have investigated the occurrence of MYD88 L265P mutation in adult patients with DLBCL and its relation to clinical and biological characteristics, including patients’ outcome. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 10.431 2014 ONCOLOGY 9 / 209 = 0.043 2014 Q1 T1 HEMATOLOGY 3 / 68 = 0.044 2014 Q1 T1 info:eu-repo/semantics/other info:eu-repo/semantics/publishedVersion Bellosillo, B García-García, M (orcid)0000-0003-2078-8205 Sánchez-González, B Gimeno, E Vela, M C Serrano, S Besses, C Salar, A 28, 10 (2014), 2104-2106 Leukemia Leukemia 0887-6924 217252 http://zaguan.unizar.es/record/147841/files/texto_completo.pdf Versión publicada 2059121 http://zaguan.unizar.es/record/147841/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:147841 articulos driver 2025-01-09-14:59:04 ARTICLE